Commercial Space Company Risk / Opportunity Ranking

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Camphouse after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic roundup mention was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for Capsa AI after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CardNexus after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says the reviewed sources does not provide direct company-specific evidence and references: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No positive investment thesis can be supported because the reviewed sources contain no direct positive evidence for CeQur after the 90-day recent evidence window.

Why now: There is no current catalyst in the local reviewed sources. Coverage debug shows 1 article considered but 0 articles after recent evidence window and 0 evidence available after dedupe; recency-based judgment is therefore unavailable.

Caveats: Phase-2 membership rationale says only a generic funding roundup was provided, tied to: but no is supplied in the reviewed sources so it cannot be cited as factual support. Evidence recent evidence review shows cutoff date March 29, 2026 with 0 kept rows and 0 undated rows kept.

Thesis: No reviewed sources-supported positive thesis is available. The reviewed sources explicitly says the summaries do not clearly connect CITIC Group to a qualifying space business.

Why now: There is no current catalyst. Despite 4,475 article IDs considered, the reviewed sources reports zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase2 rationale references article IDs: and: as context, but no were provided in the reviewed sources. Very large raw mention universe does not imply conviction or thesis attractiveness. Possible name/alias ambiguity is unresolved by the reviewed sources.

Thesis: No positive thesis is supported. The reviewed sources rationale says COMSAT appears only in the context of Intuitive Machines acquiring Goonhilly Earth Station/COMSAT, which is indirect and not sufficient for a company-specific opportunity view.

Why now: No 90-day article summaries or evidence were available for COMSAT in these reviewed sources, so there is no supported timing catalyst.

Caveats: Relations/context-only style mention should not be used as counterparty propagation evidence. Phase2 rationale references article ids: and: but no or summaries are provided in the reviewed sources. No direct evidence were available after recent evidence window.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale says EaglePicher is a key player in space batteries and that its systems were on NASA CLPS lunar lander missions, but no retained direct positive evidence or article summaries are available here.

Why now: No current catalyst is evidenced in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article, but the reviewed sources does not include the article summary or retained evidence. Supplier relevance to the space ecosystem does not by itself justify an opportunity score without current retained evidence. Recency is uncertain because the supporting substantive claims are not preserved in the recent evidence window evidence set.

Thesis: The reviewed sources only indicates service/testing relevance in a Sidus-related context, and it contains no retained direct positive evidence with inside the recent evidence window, so there is no supported opportunity thesis.

Why now: Why now is absent because only 2 articles were considered and none survived the 90-day filter; there is no current evidence basis for a 1 year+ directional call.

Caveats: Coverage is extremely sparse. The only described relation is context/service oriented and relations are context-only unless policy-gated. No post-cutoff evidence available.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale references IHI benefiting from ICEYE SAR satellites and planning multi-sensor integration, but no retained direct evidence or article summaries are present here.

Why now: There is no current why-now signal in the retained reviewed sources. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the actual retained evidence is absent from these reviewed sources. The rationale itself frames IHI more as a beneficiary/customer than clearly as the core space operator, which weakens directional use even if the older article were available.

Thesis: No direct positive evidence is available, and the reviewed sources say the included summaries do not clearly establish what Island Green Capital is.

Why now: No timing-based catalyst is supported because no post-recent evidence window evidence were available.

Caveats: Phase2 rationale references article IDs: and: but no were provided in the reviewed sources. Reviewed evidence states summaries were about Molten Ventures and Isar Aerospace rather than clearly about Island Green Capital. Context-only mentions cannot support propagation.

Thesis: No positive thesis is supportable from retained reviewed sources evidence because there are no direct positive evidence and no articles retained after the 90-day recent evidence window.

Why now: There is no current why-now signal in the reviewed evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after dedupe/recent evidence window.

Caveats: Phase-2 rationale references article: but that article content is not provided here and no retained evidence remain after recent evidence window. Membership review status is not directional proof. Absence of evidence should not be interpreted as absence of business activity.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale describes air-launch and testing platform exposure, but no retained direct positive evidence or article summaries are provided here.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window despite substantial historical article count.

Caveats: Phase-2 rationale references articles: and: but their content is not included here. Historical mention density is not conviction. Public listing/ticker presence does not create a directional thesis without retained evidence.

Thesis: No positive thesis is supportable from retained reviewed sources evidence. The phase-2 rationale notes a letter of intent related to debris removal services, but no direct retained evidence row or article summary is provided in these reviewed sources.

Why now: No current why-now signal is available in the retained evidence. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window.

Caveats: Phase-2 rationale references article: but the underlying article details are not included here. A referenced letter of intent, without retained evidence details or timing, is insufficient for a 1 year+ directional ranking. Private-company status may limit visibility, but that is not itself a thesis.

Thesis: No supported positive thesis. The reviewed sources say SWISSto12 is only mentioned in passing in an article about SpaceLocker, which is provisional single-article context and not company-specific evidence, unavailable in reviewed sources).

Why now: There is no identifiable catalyst because the reviewed sources provide only a passing mention and no direct event or fact evidence.

Caveats: No current evidence is provided for. Support level is provisional single-article context only. No evidence available after recent evidence window.

Thesis: No positive thesis is supported. Veact appears only via a broad funding roundup and is not linked to a space-specific category in the reviewed sources.

Why now: No why-now catalyst is supported because the reviewed sources contain no post-recent evidence window evidence.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. A broad funding roundup is not enough to establish thesis direction. Coverage data shows articles after recent evidence window = 0.

Thesis: No direct positive evidence is available. The reviewed sources only says Volteum surfaced from a general funding roundup with no space-specific linkage.

Why now: No catalyst is supported in the reviewed sources due to zero post-recent evidence window evidence.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. Funding-roundup presence alone is not directional proof. Evidence strength remains minimal.

Thesis: No reviewed sources-supported positive thesis is available. Zaro is only listed in a general funding roundup with no direct linkage to a qualifying space thesis.

Why now: There is no current or durable catalyst supported by the reviewed sources because no evidence survived into the available post-recent evidence window set.

Caveats: Phase2 rationale references article: but no was provided in the reviewed sources. General funding-roundup context is weaker than direct event or fact evidence. Coverage remains insufficient for a directional call.

Thesis: No positive thesis can be supported from the reviewed sources because there is no direct positive evidence available for Zone14 within the 90-day recent evidence window.

Why now: There is no current company-specific catalyst visible in the reviewed sources. Coverage debug shows zero articles after recent evidence window and zero evidence after recent evidence window for Zone14; the membership note says it appears only through a broad funding roundup and lacks company-specific evidence tied to the listed scope.

Caveats: No current evidence is provided in the reviewed sources for the cited membership-support article Evidence recent evidence review shows 0 kept rows after the March 29, 2026 cutoff. Company appears only in review status with low membership confidence, which is not directional evidence.

Thesis: Execution risk remains meaningful because the key value inflection still depends on MIURA 5 development and inaugural test-flight timing later in 2026 rather than already-proven orbital commercial cadence.

Why now: The reviewed sources show a sequence of material developments: €180 million Series C on March 4, 2026, €30 million EIB venture debt signed April 7, 2026 and reported May 6, 2026/04-07, first commercial contract reported May 21, 2026, and €35 million Kourou launch-complex investment on June 1, 2026 while MIURA 5 remained on track for a late-2026 first test flight. That is strong state-change evidence for a 1 year+ horizon.

Caveats: Risk evidence is partly inferred from dependency on future launch milestones rather than a disclosed adverse event. Most support is supporting article context, though the chronology is consistent and material.

Thesis: Risk is moderate because the reviewed sources' key opportunity is still relatively early in size and scope compared with SpaceX, and execution must extend from launch into GEO satellite production and operation.

Why now: The main catalyst is the May 2026 award of Rocket Lab's first GEO satellite production program for the U.S. Space Force, which extends the company into a new orbital regime and broadens its mission model. That is paired with evidence of ongoing launch execution on May 22, 2026 through the ninth dedicated Electron mission for Synspective.

Caveats: The reviewed sources contain no direct negative events, so risk is mainly execution-based rather than explicitly evidenced adverse news. One representative item references stock performance but is undated and should not be treated as reliable recency proof.

Thesis: Risk remains meaningful because the reviewed sources classifies the available evidence mostly as weak supporting article context rather than direct positive events/facts, and there is no available direct evidence for commercial revenue conversion, deployment success, or execution milestones beyond the grant and partnership narratives

Why now: Why now is strong because the June 11-22, 2026 evidence sequence shows fresh capital support first, then a later strategic partnership, suggesting opportunity maturation within weeks rather than stale background context

Caveats: Most evidence is supporting article context or weak context rather than direct positive events. Same-story repetition around the grant should not be treated as independent confirmation. No direct available evidence of revenue, backlog conversion, or deployment milestones.

Thesis: Risk remains meaningful because the reviewed sources' usable support is mostly supporting article context rather than direct positive events, and the financing is growth capital for a private company rather than proof of commercial conversion at scale.

Why now: A dated May 6, 2026 article says Scout raised up to $18 million Series A and will use the capital for mission execution and expansion of manufacturing capabilities, creating a current capacity-building milestone for the next year, May 6, 2026).

Caveats: Most available support is weak context/supporting article context rather than direct positive events. Blue Origin partnership articles are from 2025 and were outside the 90-day recent evidence window, so they should not drive recency-based ranking

Thesis: The main risk is launch execution risk because the reviewed sources frames Vikram-1 as a preparation-stage maiden orbital mission rather than an already completed orbital launch, and there is no additional direct evidence in the reviewed sources showing later de-risking.

Why now: The relevant dated development is the reported financing on May 7, 2026 alongside the stated approach to the Vikram-1 maiden flight, which fits a 1 year+ thesis if execution progresses.

Caveats: Support is supporting article context only; the reviewed sources have no direct positive events available for Skyroot. Same-article repeated context rows are not independent confirmation.

Thesis: Risk exists from concentration in large government programs and evidence of pricing tension with the Pentagon, but the reviewed sources does not show a material adverse operational or financial event inside the recent evidence window.

Why now: The timing is supported by late-May 2026 contract awards: a $2.29 billion Space Force data-network award dated May 26, 2026 and a $4.16 billion Space Force SB-AMTI award dated May 29, 2026/May 30, 2026, plus NASA's plan dated May 24, 2026 to add missions to SpaceX's commercial crew contract, all of which indicate durable backlog expansion and franchise entrenchment over a 1 year+ horizon.

Caveats: The reviewed sources' available source fields contain no direct positive or negative events for SpaceX; opportunity is inferred from high-materiality neutral facts and article summaries. Ticker mapping is noisy in the reviewed sources: SpaceX is shown with ticker TSLA, which should not be treated as validated public-company identity here.

Thesis: The same constellation-buildout framing also implies material execution risk because the reviewed sources provide no fresh in-window evidence confirming funding sufficiency, deployment timing, customer demand, or progress beyond the build statement.

Why now: There is no direct, dated catalyst in the available evidence. The reviewed sources references article ID: for membership support, but provides no and shows 0 evidence after recent evidence window, so current status cannot be verified.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article ID: but the reviewed sources does not include a or summary for citation.

Thesis: Risk is modestly higher than opportunity because there is effectively no fresh reviewed evidence to validate current traction, contracts, or program wins after the March 29, 2026 cutoff. The issue is not reviewed sources-proven deterioration, but lack of current support.

Why now: There is no current catalyst in the kept ranking evidence. The only representative article provided is dated February 7, 2025, outside the recent evidence window, via at

Caveats: Zero evidence were kept after the 90-day recent evidence window. The available article context is outside recent evidence window and should not be treated as current catalyst evidence.

Thesis: Starcloud also carries meaningful execution risk because the reviewed sources evidence frames the business around an extremely ambitious proposed constellation scale and supporting article context rather than direct company events. The May 26, 2026 article says the constellation ultimately envisions 88,000 orbital data centers, a very large scope that implies substantial execution and capital intensity risk.

Why now: Within the 90-day recent evidence window, Starcloud has the clearest sequence of dated business-state updates: funding on March 30, 2026, network-equipment contract on May 26, 2026, and additional context on capital raised and market positioning on June 10, 2026, For a 1 year+ horizon, that sequence supports an active buildout story even though evidence quality is not fully direct.

Caveats: All usable evidence is supporting article context; the reviewed sources provide no direct positive or negative dated event/facts. Repeated Starcloud claims across articles are not independent confirmation under the evidence standard. Opportunity and risk both remain dependent on future execution over a long horizon.

Thesis: The same rationale also implies significant technology and commercialization risk: pre-seed stage, advanced propulsion development, and no available proof of contracts, flight validation, or revenue traction in the reviewed sources.

Why now: Why now is relatively better than peers because the rationale includes a recent capital raise and a specific product focus, both of which can influence a 1 year+ strategic trajectory, though no direct dated evidence are available to verify recency sequencing.

Caveats: Membership rationale cites article IDs: and: but no are present. The reviewed sources contain no direct positive or negative evidence arrays despite the financing statement in the rationale. Early-stage propulsion development is inherently high-uncertainty, but that is inferred from stage and product type, not from a available adverse article.

Thesis: Risk is modest because there is too little available evidence after recent evidence window to support a stronger positive or negative view, making outcome uncertainty high.

Why now: The membership rationale references selection for IN-SPACe funding and AI-powered star tracker work using article IDs, and: but no article summaries, or direct evidence are available in these reviewed sources after recent evidence window, so recency and materiality cannot be independently verified from the evidence body.

Caveats: No representative articles, or available evidence available to cite directly beyond membership rationale. Coverage debug shows zero article IDs after recent evidence window and zero evidence after recent evidence window. Scoring is conservative because reviewed sources support is incomplete in the visible evidence section.

Thesis: Risk remains meaningful because the reviewed sources provide only thin support beyond the financing statement; there is no available kept direct positive event detail, customer traction, deployment milestone, or contract evidence to validate execution progress.

Why now: The 'why now' is the capital raise described in the reviewed sources' membership rationale via article: but the ranking payload does not include the article or a richer reviewed evidence row, so recency and detail are only partially grounded.

Caveats: The reviewed sources does not provide the article for the cited membership-support article. This is mainly a financing-backed opportunity thesis, not a contract- or revenue-backed one in these reviewed sources.

Thesis: Risk is moderately elevated because, despite the promising rationale, the reviewed sources show no representative article details, no direct positive evidence, and zero article IDs after recent evidence window in coverage debug. That creates substantial verification and timing uncertainty.

Why now: Why now is only moderate because the membership rationale references support references including, and: but the reviewed sources does not provide or article summaries for them. Without visible dated article detail, the near-current business state cannot be confirmed.

Caveats: Important claims appear only in the membership rationale; no -bearing direct evidence is exposed. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

Thesis: Risk remains meaningful because the company is tied to a demanding defense-space interceptor effort, and one source notes $50 million of the financing was debt, which adds some balance-sheet/obligation risk. In addition, much of the evidence comes from external articles and company-associated announcements rather than a broader set of independently available direct events.

Why now: The recent sequence matters: on April 28, 2026, True Anomaly announced a $650 million Series D at a $2.2 billion valuation, also. Then on May 4, 2026, a dated article said the company was selected by the U.S. Space Force Space Systems Command for the Space-Based Interceptor program. That capital-plus-program sequence is directly relevant to a long-horizon growth thesis.

Caveats: Most evidence is external overlay context/facts rather than primary data source direct events. Several sources repeat the same April 28 financing story and are not independent confirmation of different events. The company-site article is undated, so recency-sensitive claims from it should be treated cautiously.

Thesis: Even with the stated Series B and launch success, launch-vehicle companies remain execution- and capital-intensive, and the reviewed sources provide no available evidence on follow-on contracts, cadence, or economics. Risk is therefore still elevated.

Why now: Why now is relatively stronger because the rationale includes both funding and a technical milestone, which are durable indicators for a 1 year+ horizon, though exact dates and chronology cannot be checked from the reviewed sources' empty post-recent evidence window evidence tables.

Caveats: Membership rationale cites article IDs: and: but no are given. No direct events or summaries are available after recent evidence window, so success claims cannot be quoted from the reviewed sources. Opportunity and risk both reflect a capital-intensive launch model with limited reviewed sources verification.

Thesis: The same evidence implies meaningful execution risk: building a satellite network is capital intensive and ambitious, while the reviewed sources offers only one supporting article and no direct follow-on customer, launch, or technical milestone evidence.

Why now: Why now is the claimed funding event and network build plan referenced in article ID: but the reviewed sources does not provide the article or detailed timestamp, so recency is only partially grounded.

Caveats: The key claim comes from membership rationale rather than available direct evidence. Article ID: is referenced without a. No evidence of downstream execution, contracts, launches, or adoption is present.

Thesis: Risk is elevated because the reviewed sources does not expose the underlying article summaries or -bearing evidence for those contract claims inside the ranking section, and coverage debug shows zero article IDs after recent evidence window and zero evidence available after recent evidence window. That leaves execution and verification risk high.

Why now: Why now is only moderate because the membership rationale references significant contracts via support references including: but the reviewed sources provide no or representative article detail for citation-quality corroboration. The forecast horizon of 1 year+ could fit contract conversion and constellation expansion if current, but recency cannot be validated from visible article rows.

Caveats: The contract and expansion claims appear only in membership rationale text; no representative article with is included. Coverage debug shows articles after recent evidence window = 0 and evidence after recent evidence window = 0.

Thesis: Risk remains elevated because the same body of context portrays Vast as pursuing multiple capital-intensive initiatives at once—commercial space stations, NASA contract competition, and now satellite manufacturing. Earlier dated March items about a $500 million raise were outside the recent evidence window and therefore cannot be primary support here, so the retained case still relies on supporting article context rather than direct event/facts, leaving execution and commercialization risk significant, May 19, 2026, May 19, 2026).

Why now: The timing case is stronger than peers because the product expansion articles are dated May 19, 2026 and May 20, 2026, within the 90-day recent evidence window, and represent a potentially durable strategic change: moving into satellite buses rather than remaining only a station developer, May 19, 2026, May 20, 2026).

Caveats: Retained evidence is weak context supporting article context; there are no direct positive event/facts available. The March 2026 financing articles are outside the 90-day recent evidence window and cannot be primary support, even though they appear in representative articles. Several retained rows summarize the same basic product announcement and should not be treated as independent confirmation.

Thesis: Execution risk appears elevated because the thesis depends on a planned constellation and post-quantum satellite rollout, yet the reviewed sources lack fresh evidence validating current status. With no direct negative event available, the risk score is driven by uncertainty around plan-to-execution conversion rather than confirmed deterioration.

Why now: There is no documented near-term catalyst in the available evidence. Membership support cites article IDs and, but the reviewed sources reports 0 article IDs after recent evidence window and 0 evidence after recent evidence window.

Caveats: No direct evidence available after recent evidence window for this company. Membership rationale references article IDs and, but the reviewed sources does not include or article summaries for citation. Risk is inferred from lack of current execution proof, not from a confirmed adverse event.

Thesis: Risk is moderate because the available evidence is undated supporting article context from the company site. Since the basis is explicitly 'undated,' recency-sensitive claims about current constellation readiness, capacity, and commercial position are uncertain.

Why now: Why now is weak because the evidence retained is undated and the reviewed sources explicitly says to treat recency-sensitive claims cautiously when no is available. The underlying strategic area may be attractive, but current business-state confirmation is missing.

Caveats: Evidence is undated, so current-state claims are less reliable for timing judgments. Only supporting article context is provided, not direct event evidence. No direct customer, contract, financing, or negative-event evidence is shown.